Atlas Trials

Recurrent Vulvovaginal Candidiasis

13 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Vulvovaginal Candidiasis

RecordFirmDate
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study (NCT06190509)LimmaTech Biologics AG2023-12-06
Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis (NCT05795491)Cairo University2023-04-01
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis (NCT05074602)Jiangsu HengRui Medicine Co., Ltd.2021-09-14
Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis (NCT04639544)Biosearch S.A.2021-02-15
Study of Lactobacillus in Adjuvant Treatment of RVVC (NCT04699240)Peking University Shenzhen Hospital2020-07-01
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) (NCT04029116)Scynexis, Inc.2019-10-21
A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) (NCT04734405)ProFem GmbH2019-10-01
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections (NCT03840616)Mycovia Pharmaceuticals Inc.2019-03-13
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (NCT03561701)Mycovia Pharmaceuticals Inc.2018-08-23
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (NCT03562156)Mycovia Pharmaceuticals Inc.2018-08-16
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (NCT03059992)Scynexis, Inc.2017-04-01
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (NCT02267382)Viamet2015-02-10
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection (NCT01067131)Pevion Biotech Ltd2010-03-01

Track Recurrent Vulvovaginal Candidiasis automatically

Every clearance here is in the API, with alerts when new ones post.